News

The data show that topical application of AKP-11 was safe, well-tolerated as well as resulted in a significant reduction in plaque severity. The company said that no detectable

"In mid-2013 we announced that we had received notification that our patent and trademarks for the Nyloxin® line of pain relievers had been published in India’s Official Journal,

The agreement will strengthen AstraZeneca’s aclidinium respiratory franchise and is expected to add immediate revenues with long-term growth potential. Upon completion of the transaction, AstraZeneca will own the

Valued at $90 per Hospira share, the acquisition is expected to improve Pfizer’s Global Established Pharmaceutical (GEP) Business as well as strengthen its portfolio of generic injectable drugs

The patented cotton enhanced insulating materials used in all the packaging products offer soft cushioning thermal protection. The packaging, post-use, is disposable by the customer as ordinary household

As part of the deal, the two parties will focus on preclinical research involving QR Pharma’s lead drug candidate Posiphen. The deal will see investigators at Rockefeller conduct

The IND acceptance allows the company to start a Phase I/II clinical trial of the ZFP Therapeutic in transfusion-dependent patients with beta-thalassemia major. Scheduled to begin in 2015,

Around 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation will

The phase 3 clinical program across Asia includes the REDUCER (An Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopathic